Insider Transactions in Q4 2024 at Bio Xcel Therapeutics, Inc. (BTAI)
Insider Transaction List (Q4 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
165
-0.82%
|
$0
$0.35 P/Share
|
|
Dec 16
2024
|
Javier Rodriguez Officer |
SELL
Open market or private sale
|
Direct |
430
-0.87%
|
$0
$0.36 P/Share
|
|
Dec 16
2024
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
577
-1.35%
|
$0
$0.36 P/Share
|
|
Dec 16
2024
|
Vimal Mehta CEO and President |
SELL
Open market or private sale
|
Direct |
3,117
-2.52%
|
$0
$0.36 P/Share
|
|
Dec 16
2024
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
430
-0.73%
|
$0
$0.36 P/Share
|
|
Dec 15
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
562
+2.21%
|
-
|
|
Dec 15
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
562
+2.56%
|
-
|
|
Dec 15
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
3,500
+5.35%
|
-
|
|
Dec 15
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
562
+1.88%
|
-
|
|
Dec 14
2024
|
Vincent O'Neill Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+2.52%
|
-
|
|
Dec 14
2024
|
Javier Rodriguez Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+2.1%
|
-
|
|
Dec 14
2024
|
Richard I Steinhart Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+2.44%
|
-
|
|
Dec 14
2024
|
Vimal Mehta CEO and President |
BUY
Exercise of conversion of derivative security
|
Direct |
2,610
+4.28%
|
-
|
|
Dec 14
2024
|
Frank Yocca Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
521
+1.78%
|
-
|
|
Nov 30
2024
|
David J. Mack Director |
BUY
Exercise of conversion of derivative security
|
Direct |
27,089
+50.0%
|
-
|
|
Oct 03
2024
|
Frank Yocca Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
7,175
-20.24%
|
$0
$0.55 P/Share
|
|
Oct 03
2024
|
Javier Rodriguez Officer |
SELL
Open market or private sale
|
Direct |
6,863
-22.4%
|
$0
$0.55 P/Share
|
|
Oct 03
2024
|
Matthew T. Wiley Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,272
-24.81%
|
$0
$0.55 P/Share
|
|
Oct 03
2024
|
Vincent O'Neill Officer |
SELL
Open market or private sale
|
Direct |
5,556
-22.09%
|
$0
$0.55 P/Share
|
|
Oct 03
2024
|
Richard I Steinhart Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,175
-26.13%
|
$0
$0.55 P/Share
|